That is the topic from my article out today at The Evidence Base. An excerpt is below:
On May 12, 2025, President Trump issued an executive order calling for “most favored nation” (MFN) drug pricing in the US. Key questions you may have include:
▪ What is MFN pricing?
▪ Which countries will be included in the MFN basket?
▪ How much lower are drug prices ex-US vs US?
▪ How should I evaluate MFN? What is the overall goal of drug pricing?
▪ Why do drug prices vary by country? Is this a good thing?
▪ What has happened when other countries have implemented international reference pricing?
Let’s answer each of these questions one by one. I’ve included some key readings to help you come up to speed quickly on this issue.
To find my responses to each of these questions (with key additional readings) head over to the full article on The Evidence Base here.
